the ability of active specific immunotherapy to enhance immune responses to autologous tumor-associated antigens ( taa ) and to prolong the disease-free interval was evaluated in patients with dukes b2 and c colorectal carcinoma who had undergone potentially curative resections .
C0027651
tumor
C0012634
disease